Literature DB >> 22133077

Integrating medicinal chemistry, organic/combinatorial chemistry, and computational chemistry for the discovery of selective estrogen receptor modulators with Forecaster, a novel platform for drug discovery.

Eric Therrien1, Pablo Englebienne, Andrew G Arrowsmith, Rodrigo Mendoza-Sanchez, Christopher R Corbeil, Nathanael Weill, Valérie Campagna-Slater, Nicolas Moitessier.   

Abstract

As part of a large medicinal chemistry program, we wish to develop novel selective estrogen receptor modulators (SERMs) as potential breast cancer treatments using a combination of experimental and computational approaches. However, one of the remaining difficulties nowadays is to fully integrate computational (i.e., virtual, theoretical) and medicinal (i.e., experimental, intuitive) chemistry to take advantage of the full potential of both. For this purpose, we have developed a Web-based platform, Forecaster, and a number of programs (e.g., Prepare, React, Select) with the aim of combining computational chemistry and medicinal chemistry expertise to facilitate drug discovery and development and more specifically to integrate synthesis into computer-aided drug design. In our quest for potent SERMs, this platform was used to build virtual combinatorial libraries, filter and extract a highly diverse library from the NCI database, and dock them to the estrogen receptor (ER), with all of these steps being fully automated by computational chemists for use by medicinal chemists. As a result, virtual screening of a diverse library seeded with active compounds followed by a search for analogs yielded an enrichment factor of 129, with 98% of the seeded active compounds recovered, while the screening of a designed virtual combinatorial library including known actives yielded an area under the receiver operating characteristic (AU-ROC) of 0.78. The lead optimization proved less successful, further demonstrating the challenge to simulate structure activity relationship studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22133077     DOI: 10.1021/ci2004779

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  5 in total

1.  Customizable de novo design strategies for DOCK: Application to HIVgp41 and other therapeutic targets.

Authors:  William J Allen; Brian C Fochtman; Trent E Balius; Robert C Rizzo
Journal:  J Comput Chem       Date:  2017-09-22       Impact factor: 3.376

2.  Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery.

Authors:  Vadim Bernard-Gauthier; Andrew V Mossine; Ashley Knight; Debasis Patnaik; Wen-Ning Zhao; Chialin Cheng; Hema S Krishnan; Lucius L Xuan; Peter S Chindavong; Surya A Reis; Jinshan Michael Chen; Xia Shao; Jenelle Stauff; Janna Arteaga; Phillip Sherman; Nicolas Salem; David Bonsall; Brenda Amaral; Cassis Varlow; Lisa Wells; Laurent Martarello; Shil Patel; Steven H Liang; Ravi G Kurumbail; Stephen J Haggarty; Peter J H Scott; Neil Vasdev
Journal:  J Med Chem       Date:  2019-10-21       Impact factor: 7.446

3.  Metabolic Instability of Cyanothiazolidine-Based Prolyl Oligopeptidase Inhibitors: a Structural Assignment Challenge and Potential Medicinal Chemistry Implications.

Authors:  Paolo Schiavini; Joshua Pottel; Nicolas Moitessier; Karine Auclair
Journal:  ChemMedChem       Date:  2015-05-28       Impact factor: 3.466

4.  Novel inhibitors and activity-based probes targeting serine proteases.

Authors:  Timothy E G Ferguson; James A Reihill; S Lorraine Martin; Brian Walker
Journal:  Front Chem       Date:  2022-09-28       Impact factor: 5.545

5.  istar: a web platform for large-scale protein-ligand docking.

Authors:  Hongjian Li; Kwong-Sak Leung; Pedro J Ballester; Man-Hon Wong
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.